Ariel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,250 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ariel Hurley also recently made the following trade(s):

• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Price Performance

NASDAQ:BPMC traded up $2.33 during mid-day trading on Wednesday, hitting $104.89. 1,114,529 shares of the stock traded hands, compared to its average volume of 999,285. The business’s 50-day moving average price is $93.75 and its 200 day moving average price is $95.29. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company has a market cap of $6.66 billion, a PE ratio of -49.71 and a beta of 0.61. Blueprint Medicines Co. has a 12-month low of $72.24 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. During the same period in the previous year, the business earned ($2.20) EPS. The business’s revenue for the quarter was up 126.5% on a year-over-year basis. On average, analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company cut their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. JPMorgan Chase & Co. assumed coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research note on Wednesday. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines has a consensus rating of “Moderate Buy” and an average price target of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Empirical Asset Management LLC bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $2,348,000. Exome Asset Management LLC purchased a new stake in Blueprint Medicines in the third quarter valued at approximately $3,395,000. Franklin Resources Inc. lifted its position in Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after purchasing an additional 265 shares during the last quarter. Synovus Financial Corp grew its stake in Blueprint Medicines by 4.0% in the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after buying an additional 922 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Blueprint Medicines in the 3rd quarter worth $202,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.